- Supported exchanges /
- ST /
- ELIC.ST
Elicera Therapeutics AB (ELIC ST) stock market data APIs
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden.
Elicera Therapeutics AB Financial Data Overview
| 2.1 | |
| 1.915 | |
| - | |
| 1.355 | |
| 1.985 | |
| 0.852-5.68 | |
| 61 764 K | |
| 35 093 K | |
| 12 071 K | |
| -0.1602 | |
| -0.424 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Elicera Therapeutics AB Fundamental Data is available in our Financial Data APIs
- Net Revenue 12 071 K
- EBITDA -21 627 288
- Earnings Per Share -0.89
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Elicera Therapeutics AB Earnings via APIs
- Latest Release 2024-06-30
- EPS/Forecast NaN
Get Elicera Therapeutics AB End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
